Abstract Number: 1370 • ACR Convergence 2022
Abatacept in the Treatment of Refractory Juvenile Dermatomyositis
Background/Purpose: This open-label 24-week study was conducted to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (JDM).Methods: Ten patients of…Abstract Number: 1243 • ACR Convergence 2021
Real World Validation of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis: Analysis from the RISE Registry
Background/Purpose: Accurately identifying patients who may respond better to a specific drug or mechanism of action could improve rational selection of medications to optimize clinical…Abstract Number: 1259 • ACR Convergence 2021
Association of SLE Responder Index (SRI) Attainment and Long-term Clinical Outcomes
Background/Purpose: The SLE Responder Index (SRI) is a composite responder definition employed as a clinical trial endpoint in SLE. Despite its widespread adoption, recent discrepant…Abstract Number: 1694 • ACR Convergence 2021
Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs
Background/Purpose: Sustained clinical remission (REM) is the primary treatment goal for patients with rheumatoid arthritis (RA), with low disease activity (LDA) being an appropriate target…Abstract Number: 0837 • ACR Convergence 2021
Sustainability of Response Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial
Background/Purpose: The primary treatment target for patients with active rheumatoid arthritis (RA) is sustained clinical remission (REM) or low disease activity (LDA).1,2 A greater proportion…Abstract Number: 0953 • ACR Convergence 2021
An International Delphi Exercise to Identify Items of Importance for Measuring Response to Treatment for ANCA-associated Vasculitis
Background/Purpose: ANCA-associated vasculitis (AAV) is characterized by fluctuating levels of disease activity. Randomized controlled trials (RCTs) in AAV have used multiple instruments to define active…Abstract Number: 0200 • ACR Convergence 2020
Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study
Background/Purpose: ORAL Shift, a global Phase 3b/4 non-inferiority study, demonstrated sustained efficacy/safety of tofacitinib modified-release (MR) 11 mg QD following MTX withdrawal in patients (pts)…Abstract Number: 0427 • ACR Convergence 2020
Validation of Physician Global Assessment as an Outcome Measure in Relapsing Polychondritis
Background/Purpose: Relapsing polychondritis (RP) is a rare systemic inflammatory disorder of cartilage that lacks validated disease activity measures. Physician global assessment (PhGA) is a measure…Abstract Number: 0480 • ACR Convergence 2020
Impact of Targeting Remission or Low Disease Activity on 10-year Severity in Rheumatoid Arthritis : Data from ESPOIR Cohort
Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to target remission or at least low disease activity (LDA). We previously showed that SDAI remission…Abstract Number: 0482 • ACR Convergence 2020
Differential Influence of CDAI Components Based on Disease State in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Background/Purpose: Treat-to-target recommendations for rheumatoid arthritis (RA) dictate that remission or low disease activity should be aimed. Although numerous composite indices are available, the clinical…Abstract Number: 0820 • ACR Convergence 2020
High Remission Rates in RA – Real Life Data from Bariticinib
Background/Purpose: Recent developments of targeted treatments such as targeted synthetic DMARDs (tsDMARDs) increase the chances of a sustained low disease activity (LDA) or remission state…Abstract Number: 0909 • ACR Convergence 2020
Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study
Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…Abstract Number: 1129 • ACR Convergence 2020
Discordance in Patient and Physician Assessment of Disease Activity in Relapsing Polychondritis
Background/Purpose: Relapsing polychondritis (RP) is a rare chronic disabling inflammatory condition primarily affecting cartilage tissue. Self-reported patient outcome measures, which have not been evaluated in…Abstract Number: 1352 • ACR Convergence 2020
Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes over…Abstract Number: 1490 • ACR Convergence 2020
Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials
Background/Purpose: Despite the known high inter- and intra-patient variability in analgesic responses in chronic pain, most interventional pain studies rely on single time point pain…